Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984490). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources ...

Drs John M. Kane and Delbert G. Robinson discuss psychoeducation, treatment options, and possible side effects of medication for patients experiencing their first episode of schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984489). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia...

Drs John M. Kane and Scott W. Woods discuss clinical high-risk syndrome and schizophrenia, including assessment methods, interventions, and risk indicators for future psychosis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984484). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia...

Drs John M. Kane and Christoph U. Correll discuss the importance of ongoing assessment of psychiatric comorbidities in patients with schizophrenia and its impact on outcomes and treatment decisions. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984483). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources ...

Drs John M. Kane and Jose Rubio-Lorente discuss the value of long-acting injectable formulations in reducing the risk for relapse and rehospitalization for patients diagnosed with schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984482). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources ...

Drs John M. Kane and Jonathan Meyer discuss treatment-resistant schizophrenia, how common it is, how to detect and manage it, and how delays in the initiation of treatment negatively affect patients. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources The...

Drs John Kane and Jose Rubio-Lorente discuss relapse in schizophrenia — why it occurs, how often it occurs, and what we can do about it. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969531). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://www.medscape.com/resource/schizophrenia ...

Drs John Kane and Anil Malhotra discuss neuroimaging and connectivity between various regions of the brain in patients with schizophrenia and how it impacts the pathophysiology and treatment response. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969530). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources ...

Drs John Kane and Philip D. Harvey discuss how physicians can assess cognitive functioning in patients with schizophrenia and how to utilize rehabilitation and technology to address it. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969529). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Schizophrenia...

Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer? Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969528). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources The Clozapine Handbook: Stahl's...

Drs John Kane and Stefan Leucht discuss the effectiveness and optimal dosing of antipsychotic medications in the treatment of schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969527). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Toward a Phenomenological Psychotherapy for Schizophrenia...

Drs John Kane and Christoph U. Correll discuss the major metabolic and neurologic risks associated with antipsychotic medications for patients diagnosed with schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969525). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Schizophrenia...